中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2014年
28期
2184-2187
,共4页
聂晓敏%苏利霄%周雅婧%李希平%尚明宇%魏永祥
聶曉敏%囌利霄%週雅婧%李希平%尚明宇%魏永祥
섭효민%소리소%주아청%리희평%상명우%위영상
冠状动脉疾病%阻塞性睡眠呼吸暂停低通气综合征%内皮功能%大蒜素
冠狀動脈疾病%阻塞性睡眠呼吸暫停低通氣綜閤徵%內皮功能%大蒜素
관상동맥질병%조새성수면호흡잠정저통기종합정%내피공능%대산소
Coronary artery disease%Obstructive sleep apnea hypopnea syndrome%Endothelial function%Allitridi
目的 观察大蒜素胶囊对冠心病合并阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者血管内皮功能和临床预后的影响.方法 连续入选冠心病合并OSAHS患者80例,随机分为对照组和大蒜素组.对照组给予常规治疗,大蒜素组在常规治疗基础上加用大蒜素胶囊口服,每次40 mg(2粒),3次/d,共6个月.另外,入选冠心病不合并OSAHS患者40例和健康对照者30例.采用高分辨率彩色多普勒超声仪测定患者肱动脉内皮依赖性血流介导的血管舒张功能(FMD),试剂盒检测患者血清一氧化氮(N0)和血浆内皮素-1(ET-1)水平.随访时间为1年.结果 对照组和大蒜素组患者的临床基线资料差异无统计学意义(P＞0.05).用药前,与冠心病不合并OSAHS患者相比,冠心病合并OSAHS患者的FMD和血清NO水平显著降低[(11.2±2.9)％比(7.9±1.5)％,P=0.011]和[(86.3±11.0) μmol/L比(71.1±10.6) μmol/L,P=0.007],血浆ET-1水平显著升高[(89.9±11.6) ng/L比(112.3±17.2) ng/L,P=0.025].用药6个月时,大蒜素组的FMD和血清NO水平显著高于对照组[(12.1±3.1)％比(9.1±1.6)％,P=0.020; (105.2±17.0) μmol/L比(82.4±11.1) μmol/L,P=0.001],血浆ET-1水平显著低于对照组[(77.1±9.7) ng/L比(97.8±11.0)ng/L,P=0.001].大蒜素组随访1年时严重心脏事件(MACE)发生率显著低于对照组(8.3％比15.8％,P=0.016).结论 大蒜素可改善冠心病合并OSAHS患者的内皮功能,为冠心病合并OSAHS患者的治疗提供了新方法.
目的 觀察大蒜素膠囊對冠心病閤併阻塞性睡眠呼吸暫停低通氣綜閤徵(OSAHS)患者血管內皮功能和臨床預後的影響.方法 連續入選冠心病閤併OSAHS患者80例,隨機分為對照組和大蒜素組.對照組給予常規治療,大蒜素組在常規治療基礎上加用大蒜素膠囊口服,每次40 mg(2粒),3次/d,共6箇月.另外,入選冠心病不閤併OSAHS患者40例和健康對照者30例.採用高分辨率綵色多普勒超聲儀測定患者肱動脈內皮依賴性血流介導的血管舒張功能(FMD),試劑盒檢測患者血清一氧化氮(N0)和血漿內皮素-1(ET-1)水平.隨訪時間為1年.結果 對照組和大蒜素組患者的臨床基線資料差異無統計學意義(P＞0.05).用藥前,與冠心病不閤併OSAHS患者相比,冠心病閤併OSAHS患者的FMD和血清NO水平顯著降低[(11.2±2.9)％比(7.9±1.5)％,P=0.011]和[(86.3±11.0) μmol/L比(71.1±10.6) μmol/L,P=0.007],血漿ET-1水平顯著升高[(89.9±11.6) ng/L比(112.3±17.2) ng/L,P=0.025].用藥6箇月時,大蒜素組的FMD和血清NO水平顯著高于對照組[(12.1±3.1)％比(9.1±1.6)％,P=0.020; (105.2±17.0) μmol/L比(82.4±11.1) μmol/L,P=0.001],血漿ET-1水平顯著低于對照組[(77.1±9.7) ng/L比(97.8±11.0)ng/L,P=0.001].大蒜素組隨訪1年時嚴重心髒事件(MACE)髮生率顯著低于對照組(8.3％比15.8％,P=0.016).結論 大蒜素可改善冠心病閤併OSAHS患者的內皮功能,為冠心病閤併OSAHS患者的治療提供瞭新方法.
목적 관찰대산소효낭대관심병합병조새성수면호흡잠정저통기종합정(OSAHS)환자혈관내피공능화림상예후적영향.방법 련속입선관심병합병OSAHS환자80례,수궤분위대조조화대산소조.대조조급여상규치료,대산소조재상규치료기출상가용대산소효낭구복,매차40 mg(2립),3차/d,공6개월.령외,입선관심병불합병OSAHS환자40례화건강대조자30례.채용고분변솔채색다보륵초성의측정환자굉동맥내피의뢰성혈류개도적혈관서장공능(FMD),시제합검측환자혈청일양화담(N0)화혈장내피소-1(ET-1)수평.수방시간위1년.결과 대조조화대산소조환자적림상기선자료차이무통계학의의(P＞0.05).용약전,여관심병불합병OSAHS환자상비,관심병합병OSAHS환자적FMD화혈청NO수평현저강저[(11.2±2.9)％비(7.9±1.5)％,P=0.011]화[(86.3±11.0) μmol/L비(71.1±10.6) μmol/L,P=0.007],혈장ET-1수평현저승고[(89.9±11.6) ng/L비(112.3±17.2) ng/L,P=0.025].용약6개월시,대산소조적FMD화혈청NO수평현저고우대조조[(12.1±3.1)％비(9.1±1.6)％,P=0.020; (105.2±17.0) μmol/L비(82.4±11.1) μmol/L,P=0.001],혈장ET-1수평현저저우대조조[(77.1±9.7) ng/L비(97.8±11.0)ng/L,P=0.001].대산소조수방1년시엄중심장사건(MACE)발생솔현저저우대조조(8.3％비15.8％,P=0.016).결론 대산소가개선관심병합병OSAHS환자적내피공능,위관심병합병OSAHS환자적치료제공료신방법.
Objective To explore the effects of allitridi capsules on endothelial function and clinical prognosis in coronary artery disease (CAD) patients with obstructive sleep apnea hypopnea syndrome (OSAHS).Methods A total of 80 CAD patients with OSAHS were randomly assigned to receive conventional treatment (control,n =40) and additional allitridi treatment (120 mg/day,n =40) for 6 months.Another 40 CAD patients without OSAHS and 30 healthy individuals were chosen as controls.Endothelial function was assessed by endothelium dependent flow-mediated dilation (FMD) with highdefinition color Doppler ultrasound.Serum nitric oxide (NO) and plasma endothelin-1 (ET-1) levels were determined by enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay.The duration of followup was 1 year.Results The baseline clinical characteristics were not different between control and allitridi groups (P ＞ 0.05).Compared with CAD patients without OSAHS,FMD and serum NO level were significantly lower ((7.9 ± 1.5) ％ vs (11.2 ± 2.9) ％,P =0.011 and (71.11 ± 10.62) vs (86.28 ±11.03) μmol/L,P =0.007),plasma ET-1 level was markedly higher ((112.34 ± 17.22) vs (89.87 ±11.56) ng/L,P =0.025) in CAD patients with OSAHS.At Month 6 post-treatment,FMD and serum NO level were significantly higher ((12.1 ±3.1) ％ vs (9.1 ± 1.6) ％,P =0.020 and (105.24 ± 17.01) vs (82.39 ± 11.12) μmol/L,P =0.001) and plasma ET-1 level in the allitridi group was lower ((77.12 ± 9.65)vs (97.77 ± 11.04) ng/L,P =0.001) than that in the control group.At Month 12 post-treatment,the incidence of MACE was lower in the allitridi group than that in the control group (8.3％ vs 15.8％,P =0.016).Conclusion Allitridi capsules significantly improved endothelial function in CAD patients with OSAHS.
